Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $42.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective lifted by Bank of America from $38.00 to $42.00 in a research report released on Thursday,Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts have also recently commented on TEVA. Truist Financial boosted their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. The Goldman Sachs Group boosted their target price on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Scotiabank boosted their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research note on Thursday, January 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, January 21st. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $38.78.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $30.79 on Thursday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The stock has a 50 day simple moving average of $31.88 and a 200 day simple moving average of $28.19. Teva Pharmaceutical Industries has a 52-week low of $12.88 and a 52-week high of $37.35. The firm has a market capitalization of $35.40 billion, a PE ratio of 25.66, a P/E/G ratio of 10.38 and a beta of 0.76.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.31. The business had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.Teva Pharmaceutical Industries’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts predict that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Richard Daniell sold 17,295 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $547,732.65. Following the transaction, the executive vice president directly owned 85,755 shares of the company’s stock, valued at approximately $2,715,860.85. The trade was a 16.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric A. Hughes sold 9,533 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $301,910.11. Following the transaction, the insider directly owned 107,711 shares in the company, valued at $3,411,207.37. The trade was a 8.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 920,901 shares of company stock worth $30,056,789. Insiders own 0.49% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Phoenix Financial Ltd. grew its holdings in Teva Pharmaceutical Industries by 9.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after buying an additional 3,533,800 shares in the last quarter. National Pension Service grew its holdings in shares of Teva Pharmaceutical Industries by 24.2% during the 3rd quarter. National Pension Service now owns 2,073,293 shares of the company’s stock worth $41,881,000 after purchasing an additional 404,526 shares in the last quarter. Public Sector Pension Investment Board grew its holdings in shares of Teva Pharmaceutical Industries by 11.5% during the 3rd quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock worth $13,543,000 after purchasing an additional 69,000 shares in the last quarter. Oak Harvest Investment Services acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth $1,010,000. Finally, Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 12.9% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock worth $761,455,000 after purchasing an additional 4,306,363 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.